Cargando…
Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture
Effective control of COVID-19 requires antivirals directed against SARS-CoV-2. We assessed 10 hepatitis C virus (HCV) protease-inhibitor drugs as potential SARS-CoV-2 antivirals. There is a striking structural similarity of the substrate binding clefts of SARS-CoV-2 main protease (M(pro)) and HCV NS...
Autores principales: | Bafna, Khushboo, White, Kris, Harish, Balasubramanian, Rosales, Romel, Ramelot, Theresa A., Acton, Thomas B., Moreno, Elena, Kehrer, Thomas, Miorin, Lisa, Royer, Catherine A., García-Sastre, Adolfo, Krug, Robert M., Montelione, Gaetano T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s).
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075848/ https://www.ncbi.nlm.nih.gov/pubmed/33984267 http://dx.doi.org/10.1016/j.celrep.2021.109133 |
Ejemplares similares
-
Structure function characterization of SARS CoV2 proteases for COVID19 antiviral development
por: Greene-Cramer, Rebecca, et al.
Publicado: (2022) -
Hepatitis C Virus Protease Inhibitors Suppress Virus Replication and Act Synergistically with the SARS-CoV2 Polymerase Inhibitor Remdesivir
por: Bafna, Khushboo, et al.
Publicado: (2021) -
Structural Similarity of SARS-CoV2 M(pro) and HCV NS3/4A Proteases Suggests New Approaches for Identifying Existing Drugs Useful as COVID-19 Therapeutics
por: Bafna, Khushboo, et al.
Publicado: (2020) -
Structural similarities between SARS-CoV2 3CL(pro) and other viral proteases suggest potential lead molecules for developing broad spectrum antivirals
por: Bafna, Khushboo, et al.
Publicado: (2022) -
Protocol for production and purification of SARS-CoV-2 3CL(pro)
por: Mazzei, Luca, et al.
Publicado: (2023)